BioInfra Life Science Valuation

Is A266470 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A266470 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A266470's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A266470's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A266470?

Key metric: As A266470 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A266470. This is calculated by dividing A266470's market cap by their current book value.
What is A266470's PB Ratio?
PB Ratio	n/a
Book	₩0
Market Cap	₩3.38b

A266470 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A266470's PB Ratio compare to its peers?

The above table shows the PB ratio for A266470 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.9x
A043090 TechnologyLtd	0.5x	n/a	₩22.2b
A331920 Celemics	1x	n/a	₩28.6b
A215380 WOOJUNG BIO	1.3x	n/a	₩32.3b
A114450 Green Lifescience	1x	n/a	₩35.4b
A266470 BioInfra Life Science	n/a	n/a	₩3.4b

Price-To-Book vs Peers: Insufficient data to calculate A266470's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does A266470's PB Ratio compare vs other companies in the KR Life Sciences Industry?

1 Company	Price / Book	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate A266470's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is A266470's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A266470 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A266470's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%